Forecasting Stories

Should you shadow Atara Biotherapeutics (USA Stocks:ATRA) insiders in March?

  
They say timing is everything in the stock market, and for shareholders of Atara Biotherapeutics, a biotechnology firm in the healthcare sector, this adage rings particularly true. With a 52-week high of $4.68, the stock is currently trading at a mere $0.83, a significant drop that may be causing investors to question their holdings. The company's estimated earnings per share (EPS) for the next year is projected to be a loss of $1.48, and with a short ratio of 1.9, it's clear that some investors are betting on the stock's further decline. Continue Reading...
Macroaxis uses a strict editorial review process to publish stories and blog posts. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Raphi Shpitalnik

The company, American National Bankshares, has a beta of 2.1206. This indicates that the returns of American National are highly sensitive to market fluctuations. As the market experiences ups and downs, American National's performance is expected to mirror these movements.
  over a month ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik
In the dynamic world of finance, every cloud has a silver lining. Fifth Third Bancorp (FITB), a key player in the financial services sector, has recently experienced a 1% dip in its stock price, defying the broader market trend. This has led some investors to wonder if this could be a potential buying opportunity.
  over a month ago at Macroaxis 
By Raphi Shpitalnik
Raphi Shpitalnik
As the saying goes, "The stock market is a device for transferring money from the impatient to the patient." This seems to be the case with Nicolet Bankshares (USA Stocks: NIC), a regional bank whose impressive price surge has left many investors scratching their heads. With a 52-week high of $84.94 and a current market valuation of $77.45, the bank's performance has been nothing short of remarkable. The estimated EPS for the next year stands at $6.51, a figure that suggests strong future performance.
  over a month ago at Macroaxis 
By Aina Ster
Aina Ster
Unity Bancorp (UNTY) appears to be a potential buying opportunity amid the current market adjustment. The company's Sortino Ratio, a measure used to gauge risk-adjusted return, stands at a respectable 0.07, indicating that the stock has a decent potential for profit when considering its downside risk. Moreover, the firm's Market Risk Adjusted Performance is at 0.23, suggesting that the stock has been performing well in comparison to the inherent risk.
  over a month ago at Macroaxis 
By Raphi Shpitalnik
Raphi Shpitalnik
Volatility is the friend of the long-term investor. Arrowmark Financial Corp's (NASDAQ:BANX) recent price volatility presents a unique opportunity for discerning investors. With a 52-week high of $17.99 and a low of $12.85, the company's stock has demonstrated a noteworthy range, underpinned by a beta of 0.501, indicating lower volatility relative to the broader market.
  over two months ago at Macroaxis 
By Ellen Johnson
Ellen Johnson
As we usher in the new year, all eyes are on Chindata Group Holdings (US Stocks: CD), a key player in the Information Technology Services industry. With a market valuation of $8.49 billion and a promising EPS estimate of $0.43 for the next year, the company presents a compelling investment opportunity. The stock, currently trading on NASDAQ, has shown resilience with a beta of 0.556, indicating less volatility compared to the overall market.
  over two months ago at Macroaxis 
By Vlad Skutelnik
Vlad Skutelnik
Arrowmark Financial Corp, a key player in the Financial Services sector and specifically in the Asset Management & Custody Banks industry, has been exhibiting steady growth in the market. As of the latest update on December 6, 2023, the company's stock, traded under the ticker BANX on NASDAQ, has been showing promising signs of further upside. The stock has been performing well, with a 52-week high of $17.99 and a low of $12.85.
  over two months ago at Macroaxis 
By Aina Ster
Aina Ster
Chicken Soup for the Soul Entertainment (CSSE) has recently experienced a notable price increase of 3.7%, stirring interest among investors who are tracking its performance in the Entertainment industry. Despite the company's projected loss with an EPS estimate for next year at $3.57, the stock has managed to climb above its 200-day moving average of $1.34, which could be interpreted as a bullish signal. However, with a relatively high mean deviation of 3.03 and a substantial short interest of 1.9M shares from the previous month, indicating that a significant number of investors are betting against the stock, caution is advised.
  over two months ago at Macroaxis 
By Nico Santiago
Nico Santiago
The proof is in the pudding for Sagimet Biosciences (USA Stocks: SGMT), a clinical-stage biopharmaceutical company that has been making waves in the healthcare sector. With its innovative approach to treating diseases resulting from dysfunctional lipid metabolism pathways, Sagimet Biosciences is poised for a potential upside by December 2023. The company's lead drug candidate, Denifanstat, is a fatty acid synthase inhibitor that is currently being developed for the treatment of nonalcoholic steatohepatitis and acne.
  over three months ago at Macroaxis 
By Gabriel Shpitalnik
Gabriel Shpitalnik